The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Meridian Bioscience Receives Canadian Licenses for illumigene® Mycoplasma and illumigene® Pertussis

Wednesday, May 28, 2014

Meridian Bioscience Receives Canadian Licenses for illumigene® Mycoplasma and illumigene® Pertussis

11:30 EDT Wednesday, May 28, 2014

CINCINNATI (Business Wire) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received medical device license approval from Health Canada to market two additional assays for use on their illumigene ® molecular diagnostic platform. With the addition of illumigene Mycoplasma and illumigene Pertussis, Meridian continues to expand its position in the Canadian market by providing innovative testing solutions that meet the needs of the clinical laboratory and drive improvements in patient care.

Elena LoCastro, President at Somagen Diagnostics, stated, “Somagen Diagnostics, together with Meridian Bioscience, are excited to announce the launch of the illumigene Mycoplasma and Pertussis diagnostic tests in Canada. These newly released products are uniquely efficient in the detection of the respiratory diseases associated with Mycoplasma pneumoniae and Bordetella pertussis. Canadian healthcare professionals will benefit from the accurate, reliable results with the rapid turn-around time that is generated from illumigene technology. The illumigene Mycoplasma and Pertussis tests are made for use on the illumipro-10™ Incubator/Reader and are the first stand-alone Mycoplasma and Pertussis molecular assays licensed by Health Canada. The addition of the illumigene Mycoplasma and Pertussis products to the illumipro-10 test menu offers current illumipro-10 system users within our laboratories the opportunity to further enhance their workflow and efficiencies. In addition, the launch of these new products combined with the existing illumigene test menu, offers an attractive solution for further growth and expansion of our installed system base in Canadian medical laboratories.”

Mike Shaughnessy, President of Global Diagnostics at Meridian Bioscience, stated, “We are excited to bring illumigene Mycoplasma and illumigene Pertussis to the Canadian market. These products represent a significant advancement in the improvement of healthcare through better diagnosis and a positive impact in patient outcome. Meridian products offer definitive answers and confident results, thus helping to ensure patients receive the appropriate antibiotic treatment in a timely manner without having to depend on traditional methods which often are impractical for patient management due to the lack of sensitivity and the extended amount of time to result.”

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is

Meridian Bioscience, Inc.
John A. Kraeutler, Chief Executive Officer, 513-271-3700

  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Secure Service
Customer Service
Advertising Privacy
Globe Recognition
Mobile Apps
Other Sections